Payment overview · 2025
General Payments
$1,335.88
66 reported records · 23 companies
Healthcare provider profile · identity verified
James V Maturo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KANSAS CITY, MO · NPI 1245239813
Verified facts
What the public records show
CMS Open Payments records show James V Maturo, MD received $1,335.88 in general payments during 2025 across 66 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.95 | 17.0% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.73 | 11.1% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $128.95 | 9.7% | 6 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $107.42 | 8.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.53 | 6.8% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $78.41 | 5.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.20 | 5.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.94 | 4.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.39 | 4.2% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.74 | 3.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.47 | 3.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.68 | 3.0% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $37.85 | 2.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.10 | 2.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.94 | 2.2% | 2 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $24.70 | 1.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.55 | 1.5% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $17.92 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.53 | 1.3% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $17.27 | 1.3% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $17.19 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.93 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.49 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,335.88 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $167.96 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $163.10 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $134.68 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $128.95 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.44 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.44 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $62.20 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.54 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.54 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.29 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.39 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.39 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.79 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $42.74 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $37.85 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $37.85 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.99 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| SYNJARDY Normalized: synjardy |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 28 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 61 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 152 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
152 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
61 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 731 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 158 |
| Lisinopril | Lisinopril | 567 | 152 |
| Omeprazole | Omeprazole | 548 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 124 |
| Gabapentin | Gabapentin | 434 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 385 | 107 |
| Celecoxib | Celecoxib | 384 | 78 |
| Meloxicam | Meloxicam | 376 | 81 |
| Metformin Hcl | Metformin Hcl | 350 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 91 |
| Simvastatin | Simvastatin | 322 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 316 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 76 |
| Donepezil Hcl | Donepezil Hcl | 288 | 70 |
| Losartan Potassium | Losartan Potassium | 281 | 78 |
| Tramadol Hcl | Tramadol Hcl | 273 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 233 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 55 |
| Prednisone | Prednisone | 223 | 151 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 47 |
| Trazodone Hcl | Trazodone Hcl | 190 | 43 |
| Carvedilol | Carvedilol | 186 | 51 |
| Alendronate Sodium | Alendronate Sodium | 183 | 43 |
| Furosemide | Furosemide | 176 | 53 |
| Paroxetine Hcl | Paroxetine Hcl | 176 | 41 |
| Azelastine Hcl | Azelastine Hcl | 173 | 88 |
| Pioglitazone Hcl | Pioglitazone Hcl | 171 | 42 |
| Irbesartan | Irbesartan | 168 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 160 | 50 |
| Memantine Hcl | Memantine Hcl | 155 | 34 |
| Farxiga | Dapagliflozin Propanediol | 152 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 28 |
| Potassium Chloride | Potassium Chloride | 147 | 42 |
| Amitriptyline Hcl | Amitriptyline Hcl | 142 | 29 |
| Famotidine | Famotidine | 141 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 138 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 36 |
| Metformin Hcl Er | Metformin Hcl | 132 | 37 |
| Allopurinol | Allopurinol | 126 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 124 | 32 |
| Eliquis | Apixaban | 113 | 24 |
| Azithromycin | Azithromycin | 111 | 98 |
| Jardiance | Empagliflozin | 108 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 28 |
| Montelukast Sodium | Montelukast Sodium | 107 | 23 |
| Levofloxacin | Levofloxacin | 101 | 76 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 23 |
| Sertraline Hcl | Sertraline Hcl | 96 | 27 |
| Ozempic | Semaglutide | 94 | 23 |
| Colestipol Hcl | Colestipol Hcl | 93 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 14 |
| Glimepiride | Glimepiride | 88 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 23 |
| Warfarin Sodium | Warfarin Sodium | 83 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 21 |
| Alprazolam | Alprazolam | 79 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 72 | 45 |
| Primidone | Primidone | 72 | 15 |
| Buspirone Hcl | Buspirone Hcl | 70 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 19 |
| Valsartan | Valsartan | 70 | 17 |
| Enalapril Maleate | Enalapril Maleate | 69 | 19 |
| Sucralfate | Sucralfate | 69 | 17 |
| Synthroid | Levothyroxine Sodium | 68 | 15 |
| Nabumetone | Nabumetone | 66 | 12 |
| Topiramate | Topiramate | 66 | suppressed |
| Ezetimibe | Ezetimibe | 64 | 16 |
| Midodrine Hcl | Midodrine Hcl | 64 | 14 |
| Baclofen | Baclofen | 63 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 61 | 61 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 12 |
| Atenolol | Atenolol | 52 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | 11 |
| Cephalexin | Cephalexin | 50 | 36 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Finasteride | Finasteride | 48 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 41 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 44 | suppressed |
| Lovastatin | Lovastatin | 44 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 13 |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 14 |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 14 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | 11 |
| Digoxin | Digoxin | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 28 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 14 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Nystop | Nystatin | 23 | 15 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Nyamyc | Nystatin | 22 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Klayesta | Nystatin | 15 | 11 |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Nevirapine Er | Nevirapine | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,335.88 · 66 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACTIV.A.C., AIRSUPRA, AREXVY, Auvelity, BREZTRI, COLLAGENASE SANTYL, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, MOUNJARO, MYFEMBREE, NEXLETOL, NOVOSORB BTM, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PROMOGRAN PRISMA, PURAPLY WOUND MATRIX, QULIPTA, REPATHA, REZDIFFRA, Rybelsus, SYNJARDY, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error